Editor: What To Know
- I would like to express my warmest gratitude to all the subscribers as well as to the professional team of Springvest for their work in coordinating and marketing of our investment round.
- The United States Food and Drug Administration FDA granted Breakthrough Device Designation for Bioretec's bioresorbable RemeOs™ Screw and the on-going interactive process with the FDA forms a foundation to our registration process.
- We strongly believe that our products can provide considerable benefits to patients across the world – and accordingly this will lead into increased shareholder value”, summarizes Tomi Numminen, Bioretec´s Chairman of the Board of Directors.
Bioretec´s investment round was oversubscribed and ended during the first subscription day.
The company focuses to the registration and commercialization of RemeOs™ trauma screws
”Our new production facilities are almost ready and RemeOs™ Screw registration process has been started with the U.S. FDA. The United States Food and Drug Administration FDA granted Breakthrough Device Designation for Bioretec’s bioresorbable RemeOs™ Screw and the on-going interactive process with the FDA forms a foundation to our registration process. We have a talented and motivated team and our groundbreaking pipeline consits of various next-generation bioresorbable products. We are accelerating forward to reach our operative targets”, comments Timo Lehtonen, CEO of the company.
Bioretec investment round was organized by Springvest Oy
”We have known Bioretec team extremely well already for years and wanted to organize this exciting investment round. We knew that Bioretec shares shall show strong demand in the markets”, states Päivi Malinen, Springvest’s CEO.
